[HTML][HTML] Safety and outcomes associated with the pharmacological inhibition of the kinin–kallikrein system in severe COVID-19

E Mansour, AC Palma, RG Ulaf, LC Ribeiro… - Viruses, 2021 - mdpi.com
Background: Coronavirus disease 19 (COVID-19) can develop into a severe respiratory
syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major …

Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19.

E Mansour, AC Palma, RG Ulaf, LC Ribeiro… - Viruses, 2021 - europepmc.org
Background: Coronavirus disease 19 (COVID-19) can develop into a severe respiratory
syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major …

Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19

E Mansour, AC Palma, RG Ulaf, LC Ribeiro… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Background: Coronavirus disease 19 (COVID-19) can develop into a severe respiratory
syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major …

Safety and outcomes associated with the pharmacological inhibition of the Kinin-Kallikrein system in severe COVID-19.

E Mansour, AC Palma, RG Ulaf, LC Ribeiro… - 2021 - cabidigitallibrary.org
Abstract Background: Coronavirus disease 19 (COVID-19) can develop into a severe
respiratory syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a …

Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19

E Mansour, AC Palma, RG Ulaf, LC Ribeiro… - Viruses-Basel, 2021 - bv.fapesp.br
Background: Coronavirus disease 19 (COVID-19) can develop into a severe respiratory
syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major …

[PDF][PDF] Safety and outcomes associated with the pharmacological inhibition of the kinin-kallikrein system in severe COVID-19

E Mansour, AC Palma, RG Ulaf, LC Ribeiro… - scienceopen.com
E1 55 M Symptoms> 12 days E2 63 F Symptoms> 12 days E3 58 M Symptoms> 12 days E4
43 M Symptoms> 12 days E5 71 F Symptoms> 12 days E6 56 M Symptoms> 12 days E7 75 …

Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19.

E Mansour, AC Palma, RG Ulaf… - Viruses (1999 …, 2021 - search.ebscohost.com
Abstract Background: Coronavirus disease 19 (COVID-19) can develop into a severe
respiratory syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a …

[HTML][HTML] Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19

E Mansour, AC Palma, RG Ulaf, LC Ribeiro… - Viruses, 2021 - ncbi.nlm.nih.gov
Background: Coronavirus disease 19 (COVID-19) can develop into a severe respiratory
syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major …

Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19

E Mansour, AC Palma, RG Ulaf, LC Ribeiro… - Viruses-Basel, 2021 - bv.fapesp.br
Background: Coronavirus disease 19 (COVID-19) can develop into a severe respiratory
syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major …

[引用][C] Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19

E Mansour, AC Palma, RG Ulaf, LC Ribeiro… - 2021